Clinical decision making in diabetes: Use of glucagon-like peptide-1 (GLP-1) receptor agonists in clinical practice (where, when, and which?)–Introduction

Most read articles by the same author(s)

• Scott Joy, Jeffrey Freeman, James LaSalle, Tailoring treatment for type 2 diabetes: Uncovering the HOW and NOW of GLP-1 receptor agonist therapy , Osteopathic Family Physician: Vol. 3 No. 5 (2011)
• Jeffrey Freeman, Evidence from randomized clinical trials demonstrating improved glycemic control with GLP-1 receptor agonists when used with other agents vs other combination therapy strategies , Osteopathic Family Physician: Vol. 5 No. 1 (2013)